Add to ORKGDabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activit
Dabigatran is an oral, reversible thrombin inhibitor that has shown promising results in large clini...
Since last few years a popularity of new oral anticoagulants significantly raised. There are followi...
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assay
Dabigatran etexilate is a novel, oral reversible direct thrombin inhibitor in the clinical developme...
Dabigatran etexilate is a novel, oral reversible direct thrombin inhibitor that is rapidly absorbed ...
Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in th...
BACKGROUND Direct Thrombin Inhibitors (DTIs) represent a new and promising class of anticoagulants. ...
Dabigatran etexilate is a newly developed direct thrombin inhibitor. After oral administration, this...
Thromboembolic disease is a major cause of mortality and morbidity in the developed world and is cau...
For the last 60 years warfarin has been the cornerstone for chronic anticoagulation in prevention of...
Dabigatran etexilate was recently approved by the Therapeutic Goods Administration for thromboprophy...
Thrombo-embolic disease is a major challenging clinical problem associated with significant mortalit...
Dabigatran etexilate, a pro-drug of a direct thrombin inhibitor, was approved a few years ago for no...
Oral anticoagulation is the cornerstone of stroke prevention in non-valvular atrial fibrillation (AF...
Direct thrombin-inhibitors inactivate not only free but also fibrin-bound thrombin. The group of par...
Dabigatran is an oral, reversible thrombin inhibitor that has shown promising results in large clini...
Since last few years a popularity of new oral anticoagulants significantly raised. There are followi...
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assay
Dabigatran etexilate is a novel, oral reversible direct thrombin inhibitor in the clinical developme...
Dabigatran etexilate is a novel, oral reversible direct thrombin inhibitor that is rapidly absorbed ...
Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in th...
BACKGROUND Direct Thrombin Inhibitors (DTIs) represent a new and promising class of anticoagulants. ...
Dabigatran etexilate is a newly developed direct thrombin inhibitor. After oral administration, this...
Thromboembolic disease is a major cause of mortality and morbidity in the developed world and is cau...
For the last 60 years warfarin has been the cornerstone for chronic anticoagulation in prevention of...
Dabigatran etexilate was recently approved by the Therapeutic Goods Administration for thromboprophy...
Thrombo-embolic disease is a major challenging clinical problem associated with significant mortalit...
Dabigatran etexilate, a pro-drug of a direct thrombin inhibitor, was approved a few years ago for no...
Oral anticoagulation is the cornerstone of stroke prevention in non-valvular atrial fibrillation (AF...
Direct thrombin-inhibitors inactivate not only free but also fibrin-bound thrombin. The group of par...
Dabigatran is an oral, reversible thrombin inhibitor that has shown promising results in large clini...
Since last few years a popularity of new oral anticoagulants significantly raised. There are followi...
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assay
